Amex Stock Slides on Job Cuts, But the Real Story Is Macro

American Express reported record Q3 2026 revenue of $20.1B, up 9% year over year, and adjusted EPS of $4.68, up 13%; it raised its full-year adjusted EPS range to $17.60–$17.90 while reaffirming 10% revenue growth. Net write-offs eased to 1.8%, though commercial billings grew only 3% (5% excluding portfolio exits) and the company announced a 5% workforce reduction. Shares fell 3.71% on Oct. 23; the article points to macroeconomic anxiety as a likely factor despite the strong results and guidance.

Analysis

The market is treating AXP less as a single-quarter earnings story and more as a high-frequency signal for premium-consumer and business demand. That creates asymmetric sensitivity: continued resilient travel spending can support fees and billings, but a deterioration in small-business activity could re-rate the stock before it appears in headline consumer data. Commercial billings are the watchpoint, not the headline growth rate: portfolio exits explain part of the softness, while only 2% growth in small-business goods and services suggests a weaker underlying pocket.

Credit is reassuring but not conclusive. The lower write-off rate is more useful than the provision decline, which includes a $215 million model-related reserve release; investors should separate realized credit performance from accounting-driven benefit. Likewise, fee growth and younger-account acquisition support the franchise, but do not yet prove that refreshed premium products can sustain retention and pricing without higher acquisition or rewards costs. Workforce savings funded by a one-time asset-sale gain are not, by themselves, evidence of recurring operating leverage.

Near term, the selloff may persist while macro-sensitive investors reassess the premium consumer. Over 1–3 months, follow billings, small-business trends, write-offs and guidance delivery. Over 6–18 months, the key question is whether fee-based growth compounds while credit remains controlled. The contrarian case is that the stock is being sold as a macro proxy despite no clear deterioration in reported spending or credit; the countercase is that a model reserve release and portfolio exits make the quarter less clean than the headline suggests.

Key Decisions for Investors

• Consider a staged AXP entry rather than chasing the earnings-day decline: the article identifies support near $300 and a 50-week moving average near $334. Treat a sustained break below $300—and especially the cited 52-week low near $291—as thesis deterioration; reclaiming $334 would be a useful confirmation, not a price target.
• For the next 1–3 months, monitor organic Commercial Services billings excluding exited portfolios, small-business spending, and card-member retention. A further weakening in underlying commercial growth alongside any guidance reduction would invalidate the premium-consumer resilience thesis.
• Do not extrapolate the provision decline as a clean credit inflection. Track net write-offs and 30-day delinquencies separately from reserve changes; a reversal in those operating measures would raise downside risk and could overwhelm fee growth.
• No strong relative-value trade in LOW, AMZN, or GBTG follows from this report alone: the cited portfolio exits are AXP-specific, and the article provides no evidence of material earnings effects for those companies. Reassess only with disclosure on the scale and profitability of the exited portfolios.